Stock Taper
SCREENER COMPARE ANY 2 STOCKS
FDMT
4D MOLECULAR THERAPEUTICS, INC.
NASDAQ
$14.67
▼ DOWN 1.61% (-0.24)

KEY STATISTICS

Market Cap$766.89 M
52w High$16.93
52w Low$5.97
Dividend Yield—
Frequency—
P/E-5.71
Volume1.10M
Shares Out.52.28M

COMPANY

LEADERSHIP

David H. Kirn
CHIEF EXECUTIVE
David H. Kirn

COMPENSATION 2026

Salary$667,252
Stock Awards$0
Incentive Plan Pay$560,597
All Other Comp.$744
Total$2,051,343

ABOUT

SECTOR
Healthcare
WENT PUBLIC
December 11, 2020
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
196

PRICE TARGET

Target High$32.00
Target Low$32.00
Target Median$32.00
Target Consensus$32.00

UPCOMING EARNINGS

DateNov 10, 2026
DayTuesday
Rev. Est.$3.46M
NOV
10
TUE

PRICE

$14.67 ▼ DOWN 1.61% (−$0.24)
$14.20$14.40$14.60$14.809:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM14.67

About 4D Molecular Therapeutics, Inc.

https://www.4dmoleculartherapeutics.com ↗

4D Molecular Therapeutics is a clinical-stage gene therapy company developing AAV vector-based treatments for ophthalmology, cardiology, and pulmonology, with multiple candidates in Phase 1/2 trials and collaborations with major biotech firms.

INDUSTRY

Biotechnology

A PRODUCT 4D MOLECULAR THERAPEUTICS, INC. IS KNOWN FOR

4D-150
4D-150

An investigational genetic medicine delivering sustained anti-VEGF proteins via a single low-dose intravitreal injection to treat wet AMD and DME, aiming to reduce the need for frequent treatments.

COMPETITORS

COMPETITOR
EYPT COMPARE
MGTX COMPARE
OCUL COMPARE
RGNX COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Collaboration And License Revenue$90K $85.09M ▲$3.05M ▼$3.78M ▲

Revenue by Geography

MapREGIONQ3-2024Q4-2024Q1-2026Q2-2026
JAPAN— — $2.96M $3.69M ▲
UNITED STATES$3K $6K ▲$90K ▲$90K

ETFS HOLDING THIS STOCK

ETFS HOLDING
107
LISTED HERE
17
RANKED BY POSITION SIZE
XBI
0.21% · 1.7M
VTS.AX
0.00% · 1.6M
IWM
0.02% · 1.2M
D5BM.DE
0.05% · 310.6K
FESM
0.05% · 213.4K
SCHA
0.01% · 191.4K
DFAS
0.02% · 171.0K
AVSC
0.05% · 107.9K
PRFZ
0.04% · 86.4K
SBIO
0.39% · 64.7K
LABU
0.15% · 62.4K
BBC
1.01% · 35.5K
RSSL
0.02% · 21.8K
RFLR
0.07% · 4.8K
BIB
0.03% · 1.9K
VETS
0.03% · 1.1K
RESM
0.02% · 91

INSTITUTIONAL OWNERSHIP

SHARES OWNED
87.40%
HOLDERS
214
TOP 12 OF 214 · RANKED BY POSITION SIZE
Ra Capital Management, L.P.
5.7M sh · $42.4M
Janus Henderson Group Plc
5.2M sh · $48.87M
Blackrock Inc.
4.9M sh · $102.79M
Bvf Inc/Il
4.6M sh · $40.23M
Blackrock, Inc.
4.5M sh · $60.46M
Goldman Sachs Group Inc
4.3M sh · $32.27M
Novo Holdings A/S
3.7M sh · $33.99M
Vanguard Group Inc
3.1M sh · $23.2M
State Street Corp
2.9M sh · $38.72M
T. Rowe Price Investment Management, Inc.
2.5M sh · $33.41M
Adage Capital Partners Gp, L.L.C.
2.2M sh · $29.91M
Armistice Capital, LLC
2.0M sh · $26.6M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book3
Overall Score2

INSIDER TRADES

★
DIRECTOR, OFFICER: SEE REMARKS
Kirn David
Sale · 43.1K shares
2026-08-19
★
DIRECTOR, OFFICER: SEE REMARKS
Kirn David
Purchase · 50.0K shares
2026-08-19
★
DIRECTOR, OFFICER: SEE REMARKS
Kirn David
Sale · 25.9K shares
2026-08-19
★
DIRECTOR, OFFICER: SEE REMARKS
Kirn David
Sale · 50.0K shares
2026-08-19

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 2
OUTPERFORM 1
OVERWEIGHT 1
4 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. BUY RBC Capital OUTPERFORM Chardan Capital BUY Barclays OVERWEIGHT

SECTORS PEERS

PEERPRICE
OMER$18.61COMPARE
LXRX$2.29COMPARE
RGNX$9.66COMPARE
PRTA$9.33COMPARE
CMPX$2.40COMPARE
BCYC$4.20COMPARE
NMRA$1.39COMPARE
ADCT$1.14COMPARE